News

The increase results from the recognition as revenues during the first quarter of 2010 of EUR7.42m corresponding to the initial license payment received from Bausch + Lomb following

Dynavax Technologies said that this starts a 12-month follow-up on these subjects and sets the study’s completion for May 2011. The event supports its goal of a BLA

Stem and regenerative cells were prepared and made available at the point-of-care using the Celution System, the cell processing device developed by trial sponsor Cytori Therapeutics. Cytori said

The initiation of this study marks the commencement of the Keryx’s Phase 3 registration program for Zerenex, which is being conducted in accordance with a special protocol assessment

Amylin Pharmaceuticals, Eli Lilly and Alkermes have claimed that Bydureon is the proposed brand name for exenatide once weekly. It is an investigational, extended-release medication for type 2

Under the agreed terms Intercell is expected to pay EUR15m to Cytos. Intercell is expected to own certain unpartnered monoclonal antibody assets, including promising pre-clinical anti-infective antibody candidates

PF-04523655 is a chemically-modified siRNA drug candidate being co-developed by Quark and Pfizer for the treatment of wet age-related macular degeneration (wet-AMD) and diabetic macular edema (DME). According

TB-402 is a new, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism (VTE) following orthopaedic surgery. The Phase II

URL Pharma said that these new dosing recommendations were issued as a result of several clinical studies designed and conducted by URL Pharma that uncovered the risk of